Genmab Announces Lift of Zalutumumab Partial Clinical Hold
Genmab A/S announced that the US food and Drug Administration (FDA) has lifted the partial clinical hold on zalutumumab studies being conducted under an US Investigational New Drug application. Enrolment of patients can now resume in the Phase II study in patients with head and neck cancer considered incurable with standard treatment and the Phase I/II front line study of zalutumumab in combination with chemo-radiation.
"We have worked diligently to meet the FDA's request for additional zalutumumab safety information and are pleased that enrolment in the studies can be resumed so quickly," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We continue to believe zalutumumab could provide an important new treatment option for head and neck cancer patients with unmet medical needs."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.